论文部分内容阅读
目的:探讨索他洛尔联合稳心颗粒对心动过速患者心率及血浆血管紧张素Ⅱ(AngⅡ)与血管活性肠肽(VIP)含量的影响。方法:收集医院收治的阵发性室上性心动过速患者56例,随机分为对照组和实验组,每组各28例,对照组给予盐酸索他洛尔片口服治疗,实验组在对照组基础上给予稳心颗粒口服治疗,治疗周期为2周,治疗结束后,对所有患者的血浆AngⅡ、肾素(PRA)、醛固酮(ALD)、VIP含量、心率、心率变异性情况及临床疗效进行检测。结果:治疗后,与对照组比较,(1)实验组患者心率明显较低,差异具有统计学意义(P<0.05);(2)实验组患者的SDNN、r MSSD、PNN50水平较高,SDANN水平较低(P<0.05);(3)实验组患者血浆AngⅡ、PRA、ALD含量较低(P<0.05);(4)实验组患者血浆VIP水平较高(P<0.05);(5)实验组患者总有效率较高(P<0.05)。结论:索他洛尔联合稳心颗粒能够显著升高心动过速患者血浆VIP水平,降低血浆AngⅡ、PRA、ALD水平,降低心率以及心率变异性,临床疗效显著,对临床有指导意义。
Objective: To investigate the effects of sotalol combined with Wenxin Granule on heart rate and plasma levels of angiotensin Ⅱ (Ang Ⅱ) and vasoactive intestinal peptide (VIP) in patients with tachycardia. Methods: Fifty-six patients with paroxysmal supraventricular tachycardia admitted to the hospital were randomly divided into control group and experimental group, 28 cases in each group. The control group was treated with sotalol hydrochloride tablets orally. In the control group, Group was treated with Wenxin granule orally. The treatment period was 2 weeks. After the treatment, the plasma AngⅡ, renin (PRA), aldosterone (ALD), VIP content, heart rate, heart rate variability and clinical efficacy Test. Results: Compared with the control group, (1) the heart rate of the experimental group was significantly lower (P <0.05); (2) The SDNN, r MSSD and PNN50 levels of the experimental group were higher than those of the control group (P <0.05); (3) The levels of plasma AngⅡ, PRA and ALD were lower in the experimental group (P <0.05); (4) The plasma VIP level in the experimental group was higher (P < The total effective rate in the experimental group was higher (P <0.05). Conclusion: Sotalol combined with Wenxin Keli can significantly increase the level of plasma VIP in patients with tachycardia, decrease the levels of plasma AngⅡ, PRA and ALD, decrease the heart rate and heart rate variability. The clinical effect is significant and has clinical significance.